Pharma Industry News

NICE recommends Sobi’s Kineret for first-line use in Still’s disease

Biologic therapy approved to treat systemic juvenile idiopathic arthritis and adult-onset Still’s diseaseOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]